12 results
Categories
Human Remove Human filter
Medicine type
Conditional approval Remove Conditional approval filter
Additional monitoring Remove Additional monitoring filter
Generic Remove Generic filter
Biosimilar Remove Biosimilar filter
Medicine
Orphan designations Remove Orphan designations filter
Summaries of opinion Remove Summaries of opinion filter
Application type
Post-authorisation Remove Post-authorisation filter
-
List item
Summary of opinion: Steglatro
ertugliflozin, opinion date: 16/09/2021, Positive, Last updated: 30/09/2021 -
List item
Summary of opinion: Trelegy Ellipta
fluticasone furoate, umeclidinium, vilanterol, opinion date: 25/02/2021, Negative, Last updated: 26/02/2021 -
List item
Summary of opinion: Elebrato Ellipta
fluticasone furoate, umeclidinium, vilanterol, opinion date: 25/02/2021, Negative, Last updated: 26/02/2021 -
List item
Summary of opinion: Temybric Ellipta
fluticasone furoate, umeclidinium, vilanterol, opinion date: 25/02/2021, Negative, Last updated: 26/02/2021 -
List item
Summary of opinion: Senshio
ospemifene, opinion date: 27/01/2022, Positive, Last updated: 28/01/2022 -
List item
Summary of opinion: Segluromet
ertugliflozin, metformin hydrochloride, opinion date: 16/09/2021, Positive, Last updated: 17/09/2021 -
List item
Summary of opinion: Polivy
polatuzumab vedotin, opinion date: 24/03/2022, Positive, Last updated: 25/03/2022 -
List item
Summary of opinion: Yescarta
axicabtagene ciloleucel, opinion date: 22/04/2022, Positive, Last updated: 22/04/2022 -
List item
Summary of opinion: Retsevmo
selpercatinib, opinion date: 22/04/2022, Positive, Last updated: 22/04/2022 -
List item
Summary of opinion: Nexpovio (new)
selinexor, opinion date: 19/05/2022, Positive, Last updated: 20/05/2022 -
List item
Summary of opinion: Rinvoq (new)
upadacitinib, opinion date: 19/05/2022, Positive, Last updated: 20/05/2022 -
List item
Summary of opinion: Keytruda (new)
pembrolizumab, opinion date: 19/05/2022, Positive, Last updated: 20/05/2022